Table 5.
multivariable linear mixed effects regression model for the variation of triglycerides levels after the switch from a PI- to an INI-containing regimen
| Estimate mg/dL | SE | p value | |
|---|---|---|---|
| Female vs male | –6.0 | 8.50 | 0.475 |
| Age (x one yrs more) | –0.25 | 0.37 | 0.499 |
| Baseline triglycerides (x 1 unit more) | 0.61 | 0.02 | <0.0001 |
| Statins utilization yes vs no | 15.75 | 9.26 | 0.093 |
| Concomitant TDF interruption | 4.95 | 10.05 | 0.622 |
| Time* | –10.62 | 8.76 | 0.226 |
| *ATVub vs ATV | 2.90 | 13.26 | 0.826 |
| *DRV vs ATV | –2.77 | 13.68 | 0.839 |
| *LPV vs ATV | –32.94 | 13.23 | 0.013 |
| *fAPV vs ATV | –36.81 | 17.02 | 0.031 |
Note: *The estimates refer to parameters associated to the interaction between PIs and the time unit inserted in the model which is 6 months.
Abbreviations: SE, standard error; yrs, years; ATV, boosted atazanavir; ATVub, unboosted Atazanavir; DRV, boosted darunavir; LPV, boosted lopinavir; fAPV, boosted fosamprenavir; TDF, tenofovir disoproxil fumarato; PIs, protease inhibitors; INI, integrase inhibitors.